BackgroundFrailty is a complex clinical syndrome characterized by a decline in the functioning of multiple body systems and reduced adaptability to external stressors. Dietary ω-3 fatty acids are considered beneficial dietary nutrients for preventing frailty due to their anti-inflammatory and immune-regulating properties. However, previous research has yielded conflicting results, and the association between ω-6 fatty acids, the ω-6: ω-3 ratio, and frailty remains unclear. This study aims to explore the relationship between these factors using the National Health and Nutrition Examination Survey (NHANES) database.Materials and methodsSpecialized weighted complex survey design analysis software was employed to analyze data from the 2005–2014 NHANES, which included 12,315 participants. Multivariate logistic regression models and restricted cubic splines (RCS) were utilized to assess the relationship between omega intake and frailty risk in all participants. Additionally, a nomogram model for predicting frailty risk was developed based on risk factors. The reliability of the clinical model was determined by the area under the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA).ResultsIn dietary ω-3 intake, compared to the T1 group (≤1.175 g/d), the T3 group’s intake level (>2.050 g/d) was associated with approximately 17% reduction in frailty risk in model 3, after rigorous covariate adjustments (odds ratio (OR) = 0.83, 95% confidence interval (CI): (0.70, 0.99)). In dietary ω-6 intake, the T2 group’s intake level (>11.423, ≤19.160 g/d) was associated with a 14% reduction in frailty risk compared to the T1 group (≤11.423 g/d) (OR: 0.86, 95% CI: 0.75, 1.00, p = 0.044). RCS results indicated a non-linear association between ω-3 and ω-6 intake and frailty risk. Both ROC and DCA curves demonstrated the stability of the constructed model and the effectiveness of an omega-rich diet in reducing frailty risk. However, we did not find a significant association between the ω-6: ω-3 ratio and frailty.ConclusionThis study provides support for the notion that a high intake of ω-3 and a moderate intake of ω-6 may contribute to reducing frailty risk in middle-aged and elderly individuals.

目的:运用网络药理学挖掘银翘马勃散治疗喉源性咳嗽的作用机制.方法:运用TC-MSP数据库,并将生物利用度(OB)≥30%,类药性(DL)≥0.18作为筛选条件,从而获得银翘马勃散的主要有效成分和作用靶点,同时将获得的作用靶点导入UniProt数据库提取相应的基因名称;运用Gene-Cards平台获得喉源性咳嗽的相关靶点;运用Venny 2.1.0在线工具将所获得的药物和疾病靶点取交集,并通过Cytoscape 3.8.0软件,构建中药成分-靶点网络图;运用STRING数据库构建银翘马勃散治疗喉源性咳嗽的蛋白PPI网络互作图;进行拓扑分析并筛选出银翘马勃散治疗喉源性咳嗽的核心靶点;利用Metascape数据库对药物、疾病交集核心靶点进行GO富集分析和KEGG通路富集分析.结果:筛选出银翘马勃散治疗喉源性咳嗽的76个有效成分,相对应的基因靶点215个;喉源性咳嗽相关靶点1399个;其中,木犀草素、槲皮素、山柰酚、β-谷甾醇、β-胡萝卜素、汉黄芩素、柱头甾醇等可能是银翘马勃散治疗喉源性咳嗽的关键成分;涉及AKT1、TP53、TNF、ESR1、MYC、EGFR、IL6、CAV1等26个核心靶点.KEGG通路富集结果提示这些靶点参与TNF信号通路、C型凝集素受体信号通路、RIG-I样受体信号通路、Toll 样受体信号通路、NOD样受体信号通路、IL-17 信号通路等.结论:银翘马勃散中的活性成分能通过多靶点、多通路起到治疗喉源性咳嗽的作用.

Background: Cancer is the main cause of death worldwide, and chemotherapy is the basic method of treating cancer. However, chemotherapy-induced nausea and vomiting (CINV) is the most common side effect of chemotherapy, and conventional antiemetics for the treatment of CINV also have side effects. At present, a large number of randomized controlled trials have shown that Xiang-Sha-Liu-Jun-Zi (XSLJZ) can effectively treat CINV, but there is no systematic review. Therefore, this systematic review aims to discuss the effectiveness of XSLJZ in the treatment of CINV. Methods: Search for relevant documents in the Chinese and English databases, and the search time is limited to March 2021. Databases include Embase, Cochrane Library, Web of Science, PubMed, China National Knowledge Infrastructure, Chongqing VIP Information Resource Integration Service Platform, Wanfang Data, Chinese Biomedical Literature, etc. We will search the international clinical trial registration platform and the Chinese clinical trial registration platform to find ongoing and unpublished clinical trials. Randomized controlled trial of the efficacy of XSLJZ in the treatment of CINV were collected. After screening the literature according to the inclusion and exclusion criteria, two researchers independently extracted the data. The effective rate of treatment is the main outcome indicator of this study. The secondary indicators of this study include the incidence of adverse reactions and the improvement rate of quality of life. RevMan 5.3.5 software was used for statistical analysis. Grades of Recommendation, Assessment, Development, and Evaluation system will be used to evaluate the quality evidence for each outcome. Results: This study will provide the latest evidence for the treatment of CINV by XSLJZ. Conclusion : To evaluate the efficacy of XSLJZ in the treatment of CINV. Unique INPLASY number: INPLASY202140079.